STARR CHRISTOPHER M sold $659K of MNPR

STARR CHRISTOPHER M sold 8,400 shares of Monopar Therapeutics (MNPR) at an average of $78.50 ($78.09–$79.67, $0.66M total) across 3 trades on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · STARR CHRISTOPHER M
Published Oct 5, 2026, 9:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 9:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MNPR
Bearish
medium confidence
Mentioned
$MNPR
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MNPRBearishLow
01

Why it matters

The transaction reduces insider ownership and may be interpreted as a lack of confidence, prompting short‑term price pressure.

02

Market read

Primary insider sale news for a micro‑cap biotech; modest trading relevance.

03

What to watch

Potential upcoming clinical data releases that may offset the negative signal.

Relevance 4/10Novelty 4/10Timing: filed today

Background

Form 4 filings are primary disclosures of insider transactions. This filing reports a director’s sale under a pre‑arranged 10b5‑1 plan.

Company-level read

Ticker impact

$MNPRBearishMedium confidence
Context

Director Christopher Starr sold 8,400 shares for $659K via a 10b5‑1 plan, reducing his stake to 5,173 shares.

Expected impact

likely pressure as investors price in the insider sell

Evidence & confidence

A director’s open‑market sale of $0.66 M is material for a micro‑cap biotech and often triggers short‑term selling pressure.

Market effects

Minimal; the sale does not affect the broader biotech sector.

None; impact confined to the company.

Low; no broader market relevance.

Counterpoint

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • Monopar Therapeutics

    Biotech firm (ticker MNPR) whose director sold shares.

  • Christopher Starr

    Director of Monopar Therapeutics who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MNPRMed

Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates

Monopar Therapeutics (MNPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates Wilmette, IL, November 12, 2026 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative t

$MNPRMedAI 8/10

Monopar presents Wilson disease trial data at liver conference

Monopar Therapeutics (MNPR) presented Phase 3 FoCus trial data for Wilson disease at a liver conference. Key findings include high rates of cirrhosis, neurologic, and psychiatric symptoms among patients. ALXN1840, its investigational therapy, showed positive long-term data. The trial is the largest randomized controlled study in Wilson disease.

$MNPRMedAI 8/10

Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026

Monopar Therapeutics (MNPR) presented data from its Phase 3 FoCus trial at AASLD 2026, showing significant disease burden in Wilson disease patients, including cirrhosis, neurologic, and psychiatric symptoms. ALXN1840, Monopar's investigational therapy, demonstrated long-term safety with neutral molybdenum balance and normal uric acid levels over six years.

$MNPRLow

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Monopar Therapeutics (MNPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates Wilmette, IL, August 12, 2026 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative tr

$MNPRMedAI 8/10

Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026

Monopar Therapeutics presented Phase 2 ALXN1840 (tiomolibdate choline) data at EASL 2026 for treatment-experienced Wilson disease patients. In an open-label, multicenter 48-week trial (29 patients; 24 with paired biopsies), histology showed stabilization or improvement in multiple liver measures, with no statistically significant change in hepatic copper. The company also reported significant improvements in UWDRS Part III, CGI, and EQ-5D UK, with generally nonserious Grade 1–2 adverse events.